A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

September 5, 2019

Study Completion Date

October 25, 2019

Conditions
Pterygium
Interventions
DRUG

0.1% AG-86893 Eye Drops

One drop, three times daily to the study eye for 28 days

DRUG

0.3% AG-86893 Eye Drops

One drop, three times daily to the study eye for 28 days

DRUG

Vehicle Eye Drops

One drop, three times daily to the study eye for 28 days

Trial Locations (6)

Unknown

M.T. Coroneo Pty Ltd, Randwick

H2Vision Centre, Sippy Downs

Bendigo Eye Clinic, Bendigo

Essendon Eye Clinic, Essendon

The Geelong Eye Centre, Waurn Ponds

Lions Eye Institute, Nedlands

All Listed Sponsors
lead

Allgenesis Biotherapeutics Inc.

INDUSTRY

NCT03533244 - A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia | Biotech Hunter | Biotech Hunter